MX2019013922A - Inhibidores novedosos de map4k1. - Google Patents

Inhibidores novedosos de map4k1.

Info

Publication number
MX2019013922A
MX2019013922A MX2019013922A MX2019013922A MX2019013922A MX 2019013922 A MX2019013922 A MX 2019013922A MX 2019013922 A MX2019013922 A MX 2019013922A MX 2019013922 A MX2019013922 A MX 2019013922A MX 2019013922 A MX2019013922 A MX 2019013922A
Authority
MX
Mexico
Prior art keywords
sup
diseases
map4k1
disorders
novel inhibitors
Prior art date
Application number
MX2019013922A
Other languages
English (en)
Spanish (es)
Inventor
Vinod Patel
Venkateshwar Reddy
Laxmikant Atmaram Gharat
Sachin Sundarlal Chaudhari
Sanjib Das
Ranganadh Velgaleti
Daisy Manish Shah
Malini Bajpai
Original Assignee
Ichnos Sciences S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences S A filed Critical Ichnos Sciences S A
Publication of MX2019013922A publication Critical patent/MX2019013922A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019013922A 2017-05-26 2018-05-28 Inhibidores novedosos de map4k1. MX2019013922A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511455P 2017-05-26 2017-05-26
US201762544531P 2017-08-11 2017-08-11
PCT/EP2018/063957 WO2018215668A1 (en) 2017-05-26 2018-05-28 Novel inhibitors of map4k1

Publications (1)

Publication Number Publication Date
MX2019013922A true MX2019013922A (es) 2020-08-17

Family

ID=62492619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013922A MX2019013922A (es) 2017-05-26 2018-05-28 Inhibidores novedosos de map4k1.

Country Status (10)

Country Link
EP (1) EP3630778A1 (zh)
JP (1) JP2021506735A (zh)
KR (1) KR20200011965A (zh)
CN (1) CN112601752A (zh)
AU (1) AU2018272986A1 (zh)
CA (1) CA3064975A1 (zh)
EA (1) EA201992584A1 (zh)
IL (1) IL270844A (zh)
MX (1) MX2019013922A (zh)
WO (1) WO2018215668A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089479A1 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2019373221B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
SG11202103839UA (en) 2018-10-31 2021-05-28 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020120257A1 (en) 2018-12-11 2020-06-18 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
EP3947373A1 (en) 2019-03-26 2022-02-09 Janssen Pharmaceutica NV Bicyclic hpk1 inhibitors
EP3947366A1 (en) 2019-03-26 2022-02-09 Janssen Pharmaceutica NV Hpk1 inhibitors
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CA3140017A1 (en) * 2019-07-19 2021-01-28 Aurore HICK Polyaromatic urea derivatives and their use in the treatment of muscle diseases
BR112022022669A2 (pt) 2020-05-08 2023-01-17 Halia Therapeutics Inc Inibidores de nek7 quinase
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
JP2023533850A (ja) 2020-07-15 2023-08-04 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ａｌｋ５阻害剤としてのピリドオキサジンアミノ誘導体
CN112225748B (zh) * 2020-10-20 2021-11-30 四川大学华西医院 一种具有flt3激酶抑制活性的小分子化合物及其应用
CN114539065B (zh) * 2020-11-25 2023-07-25 帕潘纳(北京)科技有限公司 制备4-硝基-2-三氟甲基苯乙酮的方法
US20240116948A1 (en) 2020-12-23 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells
EP4288437A1 (en) 2021-02-05 2023-12-13 Bayer Aktiengesellschaft Map4k1 inhibitors
AU2022255486A1 (en) 2021-04-05 2023-10-19 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022226182A1 (en) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors
CN113603635B (zh) * 2021-10-08 2021-12-24 湖南速博生物技术有限公司 一种芳香族二元羧酸酯水解脱羧的方法
CN116410203B (zh) * 2021-12-29 2024-06-25 四川大学 具有trk及其耐药突变抑制活性的化合物及其应用
CN114751874A (zh) * 2022-05-30 2022-07-15 江南大学 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用
EP4289427A1 (en) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular.
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
ES2433230T3 (es) * 2009-08-06 2013-12-10 Merck Patent Gmbh Compuestos bicíclicos novedosos de urea
EP2742043B1 (en) * 2011-08-10 2016-10-26 Merck Patent GmbH Pyrido-pyrimidine derivatives
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives

Also Published As

Publication number Publication date
JP2021506735A (ja) 2021-02-22
KR20200011965A (ko) 2020-02-04
CA3064975A1 (en) 2018-11-29
WO2018215668A1 (en) 2018-11-29
AU2018272986A1 (en) 2019-12-12
CN112601752A (zh) 2021-04-02
EA201992584A1 (ru) 2020-06-18
EP3630778A1 (en) 2020-04-08
IL270844A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2019013922A (es) Inhibidores novedosos de map4k1.
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
PH12016501796A1 (en) Heteroaryl syk inhibitors
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
EA202091484A1 (ru) 4-азаиндольные соединения
SA516380328B1 (ar) مركبات مستبدلة-8،6-دايوكسابيسيكلو[3-2-1]أوكتان-3،2-دايول asgpr كعوامل استهداف
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
MX2020006014A (es) Compuestos de diazaindol.
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
MX2020006613A (es) Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.
WO2012088015A3 (en) Substituted hydroxamic acids and uses thereof
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
MX2020008265A (es) Derivados farmaceuticos del anillo heterobiciclico 6,5.
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
MX2018014164A (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico.
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
SG11201906688VA (en) Novel ester compounds, method for the production thereof and use thereof